These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16123985)

  • 1. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
    Shin HY; Kang HJ; Park ES; Choi HS; Ahn HS; Kim SY; Chung NG; Kim HK; Kim SY; Kook H; Hwang TJ; Lee KC; Lee SM; Lee KS; Yoo KH; Koo HH; Lee MJ; Seo JJ; Moon HN; Ghim T; Lyu CJ; Lee WS; Choi YM
    Pediatr Blood Cancer; 2006 Apr; 46(4):439-45. PubMed ID: 16123985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
    Jeha S; Kantarjian H; Irwin D; Shen V; Shenoy S; Blaney S; Camitta B; Pui CH
    Leukemia; 2005 Jan; 19(1):34-8. PubMed ID: 15510203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
    Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
    Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
    Rényi I; Bárdi E; Udvardi E; Kovács G; Bartyik K; Kajtár P; Masát P; Nagy K; Galántai I; Kiss C
    Pathol Oncol Res; 2007; 13(1):57-62. PubMed ID: 17387390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
    Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasburicase for the treatment and prevention of hyperuricemia.
    Yim BT; Sims-McCallum RP; Chong PH
    Ann Pharmacother; 2003; 37(7-8):1047-54. PubMed ID: 12841818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH; Mahmoud HH; Wiley JM; Woods GM; Leverger G; Camitta B; Hastings C; Blaney SM; Relling MV; Reaman GH
    J Clin Oncol; 2001 Feb; 19(3):697-704. PubMed ID: 11157020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.
    Pui CH; Jeha S; Irwin D; Camitta B
    Leukemia; 2001 Oct; 15(10):1505-9. PubMed ID: 11587206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
    Patel KS; Lau JE; Zembillas AS; Gallagher EM
    J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA; Herrera N; Rohatgi R
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
    Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
    Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasburicase (elitek) for hyperuricemia.
    Med Lett Drugs Ther; 2002 Nov; 44(1143):96-7. PubMed ID: 12432325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.